Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC

(2022) Oladimeji Akinboro et al.   CLINICAL CANCER RESEARCH

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

(2022) Carlotta Antoniotti et al.   LANCET ONCOLOGY

The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer

(2022) Rogier Butter et al.   LUNG CANCER

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

(2021) Ahmet Sezer et al.   LANCET

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer

(2021) Wei Xiong et al.   Frontiers in Oncology

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

(2021) Masayuki Shirasawa et al.   EUROPEAN JOURNAL OF CANCER

Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

(2021) Amanda Tufman et al.   LUNG CANCER

Tumor Immunology and Tumor Evolution: Intertwined Histories

(2020) Jérôme Galon et al.   IMMUNITY

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

(2020) F. Pagès et al.   ANNALS OF ONCOLOGY

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

(2020) Giovanni Rossi et al.   Cancers

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer

(2020) Paul Hofman   Annals of Translational Medicine

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

(2020) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

(2020) Evgeny N. Imyanitov et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

(2019) Xiaoying Sun et al.   BMC CANCER

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer

(2019) Kazue Yoneda et al.   BRITISH JOURNAL OF CANCER

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer

(2018) J Adam et al.   ANNALS OF ONCOLOGY

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis

(2018) Keith E. Steele et al.   Journal for ImmunoTherapy of Cancer

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263

(2018) DAICHI FUJIMOTO et al.   ANTICANCER RESEARCH

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

(2018) Jean-David Fumet et al.   BRITISH JOURNAL OF CANCER

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

(2017) Janet Lau et al.   Nature Communications

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

(2015) Aitziber Buqué et al.   OncoImmunology

Validating Whole Slide Imaging for Diagnostic Purposes in Pathology: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center

(2013) Liron Pantanowitz et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Trial Watch: Monoclonal antibodies in cancer therapy

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

(2011) Gabriela Bindea et al.   Seminars in Immunopathology